Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease
NCT01806610 · Ultragenyx Pharmaceutical Inc · PHASE2 · withdrawn · last registry update 2022-09-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Ultragenyx Pharmaceutical Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SOST within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-02Phase 3 first posted: Amgen, Romosozumab + Bisphosphonate (NCT05972551)
- 2023-07-03Also stopped (withdrawn): Ultragenyx Pharmaceutical Inc, BPS804 (NCT03216486)
- 2023-03-14Phase 3 first posted: Ultragenyx Pharmaceutical Inc, Bisphosphonate + Setrusumab (NCT05768854)
- 2022-03-02Results posted on the registry: Ultragenyx Pharmaceutical Inc, setrusumab + zoledronic acid (optional) (NCT03118570)
- 2021-11-18Phase 3 first posted: Ultragenyx Pharmaceutical Inc, Setrusumab (NCT05125809)
- 2021-10-05Phase 3 first posted: UCB Biopharma SRL, Romosozumab + Placebo (NCT05067335)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision